Co-Authors
This is a "connection" page, showing publications co-authored by Walter M. Stadler and Blase Polite.
Connection Strength
0.633
-
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. Clin Genitourin Cancer. 2006 Mar; 4(4):275-80.
Score: 0.273
-
A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC). J Clin Oncol. 2005 Jun; 23(16_suppl):4689.
Score: 0.259
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.040
-
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
Score: 0.037
-
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
Score: 0.024